Not Biel-related I wanted to share this inform
Post# of 8891
(Total Views: 169)
Posted On: 11/09/2025 11:05:43 AM
Not Biel-related
I wanted to share this information because I see it as a significant development in the fight against stroke, heart disease and related illness.
Statin "therapy" comes with many risks...
A human clinical trial in New Zealand is testing a groundbreaking CRISPR-based therapy designed to permanently reduce LDL cholesterol, the “bad” cholesterol linked to heart disease and heart attacks. Unlike traditional treatments like statins or diet changes, this one-time gene-editing approach could eliminate the need for lifelong medication while significantly lowering cardiovascular risk.
The therapy targets a liver gene that produces PCSK9, a protein that prevents the body from clearing excess cholesterol. By deactivating this gene using CRISPR, the body naturally removes more LDL cholesterol. Early animal studies, particularly in monkeys, showed LDL reductions of up to 70% within two weeks, with effects lasting for years. Researchers deliver the CRISPR instructions via nanoparticles, avoiding viruses, which improves efficiency and safety.
If the human trial mirrors these results, this could be a revolutionary step in cardiovascular medicine, offering a permanent, low-risk solution to high cholesterol. Beyond heart health, the trial exemplifies how CRISPR could tackle common, life-threatening conditions with single-dose treatments, marking a potential new era in preventive medicine.
✅ Source / Credit:
University of Auckland / New Zealand Clinical Trials. (2025). CRISPR-Based PCSK9 Gene Editing for LDL Cholesterol Reduction. Nature Medicine.
I wanted to share this information because I see it as a significant development in the fight against stroke, heart disease and related illness.
Statin "therapy" comes with many risks...
A human clinical trial in New Zealand is testing a groundbreaking CRISPR-based therapy designed to permanently reduce LDL cholesterol, the “bad” cholesterol linked to heart disease and heart attacks. Unlike traditional treatments like statins or diet changes, this one-time gene-editing approach could eliminate the need for lifelong medication while significantly lowering cardiovascular risk.
The therapy targets a liver gene that produces PCSK9, a protein that prevents the body from clearing excess cholesterol. By deactivating this gene using CRISPR, the body naturally removes more LDL cholesterol. Early animal studies, particularly in monkeys, showed LDL reductions of up to 70% within two weeks, with effects lasting for years. Researchers deliver the CRISPR instructions via nanoparticles, avoiding viruses, which improves efficiency and safety.
If the human trial mirrors these results, this could be a revolutionary step in cardiovascular medicine, offering a permanent, low-risk solution to high cholesterol. Beyond heart health, the trial exemplifies how CRISPR could tackle common, life-threatening conditions with single-dose treatments, marking a potential new era in preventive medicine.
✅ Source / Credit:
University of Auckland / New Zealand Clinical Trials. (2025). CRISPR-Based PCSK9 Gene Editing for LDL Cholesterol Reduction. Nature Medicine.
(2)
(0)